Abstracts Archive - Page 859 of 2425 - ACR Meeting Abstracts

Abstract Number: 1509 • 2019 ACR/ARP Annual Meeting
Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Atul Deodhar¹, Philip Mease ², Paula Machado ³, Xiangyi Meng ³, Vibeke Strand ⁴ and Marina Magrey ⁵, ¹Oregon Health & Science University, Portland, OR, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁵Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS), a chronic inflammatory disease involving the sacroiliac joints and spine, is associated with pain, stiffness, disability, and reduced quality of life.1,2…
Abstract Number: 1510 • 2019 ACR/ARP Annual Meeting
Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis
Atul Deodhar¹, Philip Mease ², Proton Rahman ³, Victoria Navarro-Compán ⁴, Vibeke Strand ⁵, Theresa Hunter ⁶, David Sandoval ⁷, Jeffrey Lisse ⁷, Fangyi Zhao ⁷ and Helena Marzo-Ortega ⁸, ¹Oregon Health & Science University, Portland, OR, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Memorial University, Newfoundland, NL, Canada, ⁴University Hospital La Paz, IdiPaz, Madrid, Spain, ⁵Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is an inflammatory condition affecting sacroiliac joints and axial skeleton, characterized by fatigue, spinal pain, and sleep disturbances that negatively affect…
Abstract Number: 1511 • 2019 ACR/ARP Annual Meeting
Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Jean-Guillaume Letarouilly¹, Benoit Flachaire ², Céline Labadie ³, Jérémie Sellam ⁴, Pascal Richette ⁵, Philippe Dieudé ⁶, Pascal Claudepierre ⁷, Bruno Fautrel ⁸, Eric Houvenagel ⁹, Chi Duc Nguyen ¹⁰, Marie-Hélène Guyot ¹¹, Nicolas Segaud ¹², Frédéric Maury ¹³, Laurent Marguerie ¹⁴, Xavier Deprez ¹⁵, Jean-Hugues Salmon ¹⁶, Guy Baudens ¹⁷, Elisabeth Gervais ¹⁸, Isabelle Chary-Valckenaere ¹⁹, Pierre Lafforgue ²⁰, Damien Loeuille ²¹, Christophe Richez ²², Thao Pham ²⁰ and René-Marc Flipo ²³, ¹University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, ²Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, ³Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, ⁴Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ⁵Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ⁶Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ⁷Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁸Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁹Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, ¹⁰Rheumatology, Hospital of Béthune, Béthune, Béthune, France, ¹¹Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, ¹²Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, ¹³Rheumatology, Private Practice, Beuvry, Beuvry, France, ¹⁴Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ¹⁵Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, ¹⁶Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁷Rheumatology, Private Practice, Valenciennes, Valenciennes, France, ¹⁸CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁹Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ²⁰Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²¹Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ²²Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ²³University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France
Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this…
Abstract Number: 1512 • 2019 ACR/ARP Annual Meeting
Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results
Gozde Kubra Yardımcı ¹, Bayram Farisoğulları ¹, Alper Sarı ¹, Levent Kilic ², Berkan Armagan ³, Emre Bilgin ¹, Ertugrul Cagri Bolek ¹, Omer Karadag ⁴, Ali Akdoğan ¹, Şule Apras Bilgen ², Ali İhsan Ertenli ¹, Sedat Kiraz ² and Umut Kalyoncu⁵, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ⁴Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Enteropathic spondylitis (eSpA) is younger brother of spondyloarthritis, and the retention rate of biological DMARD in eSpA was not yet clear. The objective of this study was to…
Abstract Number: 1513 • 2019 ACR/ARP Annual Meeting
Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis
Christopher Ritchlin¹, Alexis Ogdie ², Jon Giles ³, Juan Gomez-Reino ⁴, Philip Helliwell ⁵, Lori Stockert ⁶, Pamela Young ⁶, Wael Joseph ⁶, Rajiv Mundayat ⁷, Daniela Graham ⁸, John Woolcott ⁶ and Ana Romero ⁹, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³Division of Rheumatology, Columbia University, New York, NY, ⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁵University of Leeds, Leeds, United Kingdom, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Barcelona, Spain
Background/Purpose: Obesity is highly prevalent in PsA (~45%),1 and has previously been associated with a reduced response to TNF inhibitors.2 Tofacitinib is an oral Janus…
Abstract Number: 1514 • 2019 ACR/ARP Annual Meeting
Inadequate Response Within a Year of Biologic and Oral Synthetic DMARD Treatment Initiation Among Psoriatic Arthritis Patients in the USA Real-World Setting
Shannon Grabich ¹, Anna Sheahan¹, Owen Davies ² and Robert Suruki ¹, ¹UCB Pharma, Raleigh, NC, ²UCB Pharma, Slough, England, United Kingdom
Background/Purpose: Real-world biologic persistence in PsA patients is lower compared to persistence in clinical trials. A comprehensive description of patterns of inadequate response (IR) to…
Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey¹, Victoria Navarro-Compán ², Sandra Garces ³, Xenofon Baraliakos ⁴, David Sandoval ³, Jeffrey Lisse ³, Silvia Santisteban ³, David Adams ³, Fangyi Zhao ³ and Robert Inman ⁵, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
Abstract Number: 1516 • 2019 ACR/ARP Annual Meeting
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Martin Bergman¹, Yusuf Yazici ², Laura Coates ³, Josef Smolen ⁴, M. Elaine Husni ⁵, Sven Richter ⁶, Lichen Teng ⁶ and Arthur Kavanaugh ⁷, ¹Drexel University College of Medicine, Stockholm, Sweden, ²New York University School of Medicine, New York, ³University of Oxford, Oxford, United Kingdom, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁶Celgene Corporation, Summit, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) is an outcome measure of disease activity entirely derived from patient self-reported measures (Health Assessment…
Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Iain McInnes¹, Dafna Gladman ², Atul Deodhar ³, Corinne Miceli-Richard ⁴, Peter Nash ⁵, Naveed Sattar ⁶, Nehal Mehta ⁷, Darren Asquith ⁸, Jianyuan Wang ⁹, Hanno Richards ⁹, Luminita Pricop ¹⁰ and Abhijit Shete ⁹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Oregon Health & Science University, Portland, OR, ⁴Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ⁵University of Queensland, Brisbane, Queensland, Australia, ⁶Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁸Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…
Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Matthew Thomas ¹, Gavin Shaddick ², Rachel Charlton ¹, Charlotte Cavill ³, Richard Holland ⁴, Florenzo Iannone ⁵, Giovanni Lapadula ⁶, Simona Lapriore ⁵, Jakub Závada ⁷, Michal Uher ⁸, Karel Pavelka ⁹, Lenka Szczukova ¹⁰, Prodromos Sidiropolous ¹¹, Irini Flouri ¹¹, Burkhard Moeller ¹², Michael J. Nissen ¹³, Ruediger B. Mueller ¹⁴, Almut Scherer ¹⁵, Neil McHugh¹ and Alison Nightingale ¹, ¹University of Bath, Bath, United Kingdom, ²University of Exeter, Exeter, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵University of Bari, Bari, Italy, ⁶Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy., Bari, Italy, ⁷Institute of Rheumatology, Prague, Prague, Czech Republic, ⁸Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, ⁹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ¹⁰Masaryk University, Brno, Czech Republic, ¹¹University of Crete, Crete, Greece, ¹²University Hospital Bern, Bern, Switzerland, ¹³University Hospital Geneva, Geneva, Switzerland, ¹⁴Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ¹⁵SCQM Foundation, Zürich, Switzerland
Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…
Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting
Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Gareth Jones¹, Linda Dean ¹, Ejaz Pathan ² and Gary Macfarlane ¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Toronto Western Hospital, Toronto, Canada
Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting
Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Steven Feldman ¹, Jingchuan Zhang², Diane Martinez ³, Lorena Lopez-Gonzalez ³, Elizabeth Holt Marchlewicz ³, George Shrady ³, Alan Mendelsohn ⁴ and Yang zhao ⁵, ¹Wake Forest Baptist Health, Winston-Salem, NC, ²Sun Pharmaceutical Industries, Princeton, NJ, ³IBM Watson Health, Washington, DC, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Sun Pharmaceutical Industries, Princeton
Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…
Abstract Number: 1521 • 2019 ACR/ARP Annual Meeting
Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Walter P. Maksymowych¹, Gaia Gallo ², Rebecca Bolce ³, Fangyi Zhao ², Vladimir Geneus ³, Mikkel Østergaard ⁴, Kurisu Tada ⁵, Atul Deodhar ⁶ and Lianne Gensler ⁷, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, ⁴Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁵Juntendo University School of Medicine, Tokyo, Japan, ⁶Oregon Health & Science University, Portland, OR, ⁷University San Francisco California, San Francisco, CA
Background/Purpose: IL-17 plays an important role in the pathogenesis of radiographic axial spondyloarthritis (r-axSpA). Elevated CRP levels in serum predict response to TNF inhibitors (TNFi).1-4…
Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting
Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Sergio Schwartzman¹, Atul Deodhar ², Andris Kronbergs ³, Silvia Santisteban ³, Sandra Garces ³, David Sandoval ³, Jeffrey Lisse ³, Fangyi Zhao ³, Denis Poddubnyy ⁴ and James Rosenbaum ⁵, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Oregon Health & Science University, Portland, OR, ³Eli Lilly and Company, Indianapolis, IN, ⁴Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, Portland, OR
Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting
Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Alan Menter ¹, Zoe Draelos ², Jayme Heim ³, Jeff Parno ⁴, Alan Mendelsohn⁴, Stephen Rozzo ⁴ and Christopher Griffiths ⁵, ¹Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, ²Dermatology Consulting Services, High Point, NC, USA, High Point, NC, ³West Michigan Dermatology, Holland, MI, USA, Holland, MI, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].